1. Dohlman C. The Boston Keratoprosthesis – The first 50 years: Some reminiscences. Annu Rev Vis Sci 2022;8:1– 32.

2. Priddy J, Bardan AS, Tawfik HS, Liu C. Systematic review and meta-analysis of the medium-and long-term outcomes of the Boston type 1 keratoprosthesis. Cornea 2019;38:1465–1473.

3. Colby KA, Koo EB. Expanding indications for the Boston keratoprosthesis. Curr Opin Ophthalmol 2011;22:267– 73.

4. Ortiz-Morales G, Loya-Garcia D, Colorado-Zavala MF, Gomez-Elizondo DE, Soifer M, Srinivasan B, et al. The evolution of the modified osteo-odontokeratoprosthesis, its reliability, and long-term visual rehabilitation prognosis: An analytical review. Ocul Surf 2022;24:129–144.

5. Chhadva P, Cortina MS. Long-term outcomes of permanent keratoprosthesis. Curr Opin Ophthalmol 2019;30:243–248.

6. Dohlman CH, Harissi-Dagher M, Khan BF, Sippel K, Aquavella JV, Graney JM. Introduction to the use of the Boston keratoprosthesis. Expert Rev Ophthalmol 2006;1:41–48.

7. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: Improving outcomes and expanding indications. Ophthalmology 2009;116:640–651.

8. Aldave AJ, Sangwan VS, Basu S, Basak SK, Hovakimyan A, Gevorgyan O, et al. International results with the Boston type I keratoprosthesis. Ophthalmology 2012;119:1530–1538.

9. Driver TH, Aravena C, Duong HN, Christenbury JG, Yu F, Basak SK, et al. Outcomes of the Boston type I keratoprosthesis as the primary penetrating corneal procedure. Cornea 2018;37:1400–1407.

10. Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH. Advances in Boston keratoprosthesis: Enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin 2007;47:61–71.

11. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol 2008;145:438–444.

12. Shanbhag SS, Saeed HN, Paschalis EI, Chodosh J. Boston keratoprosthesis type 1 for limbal stem cell deficiency after severe chemical corneal injury: A systematic review. Ocul Surf 2018;16:272–281.

13. Szigiato AA, Bostan C, Nayman T, Harissi-Dagher M. Long-term visual outcomes of the Boston type I keratoprosthesis in Canada. Br J Ophthalmol 2020;104:1601–1607.

14. Ahmad S, Mathews PM, Lindsley K, Alkharashi M, Hwang FS, Ng SM, et al. Boston type 1 keratoprosthesis versus repeat donor keratoplasty for corneal graft failure: A systematic review and meta-analysis. Ophthalmology 2016;123:165–177.

15. Nayman T, Bostan C, Szigiato AA, Harissi-Dagher M. Long-term outcomes following primary versus secondary Boston keratoprosthesis type 1 implantation. Br J Ophthalmol 2022;106:935–940.

16. Rahmani S, Bagheri A, Karimian F, Javadi MA, Delfazayebaher S. Vision rehabilitation with a native pintucci-type keratoprosthesis. J Ophthalmic Vis Res 2019;14:101–104.

17. Moshirfar M, Moody JJ, Barke MR, Martheswaran T, Thomson AC, Thomson RJ, et al. The historical development and an overview of contemporary keratoprostheses. Surv Ophthalmol 2022;67:1175– 1199.

18. Kanu LN, Niparugs M, Nonpassopon M, Karas FI, de la Cruz JM, Cortina MS. Predictive factors of Boston Type I Keratoprosthesis outcomes: A long-term analysis. Ocul Surf 2020;18:613–619.

19. Prabhasawat P, Chotikavanich S, Ngowyutagon P, Pinitpuwadol W. Long-term outcomes of Boston type I keratoprosthesis, and efficacy of amphotericin B and povidone-iodine in infection prophylaxis. Am J Ophthalmol 2021;232:40–48.

20. Sun JA, Manz SN, Shen LQ. Glaucoma management in patients with penetrating keratoplasty or keratoprosthesis. Curr Opin Ophthalmol 2023;34:95– 102.

21. Senthil S, Mohamed A, Shanbhag SS, Durgam SS, Bagga B, Sangwan VS, et al. Glaucoma evaluation and management in eyes with Boston type 1 and Aurolab Keratoprostheses in an Indian cohort. Cornea 2022;41:552–561.

22. Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, et al. Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea 2014;33:349–354.

23. Bhambra N, Harissi-Dagher M, Utine CA. Management of glaucoma with Boston type 1 keratoprosthesis. Arq Bras Oftalmol 2022;85:540–542.

24. Khair D, Daoud R, Harissi-Dagher M. Retroprosthetic membrane formation in Boston keratoprosthesis type 1: Incidence, predisposing factors, complications, and treatment. Cornea 2022;41:751–756.

25. Park J, Phrueksaudomchai P, Cortina MS. Retroprosthetic membrane: A complication of keratoprosthesis with broad consequences. Ocul Surf 2020;18:893–900.

26. Khair D, Salimi A, Harissi-Dagher M. Vitreoretinal complications in Boston keratoprosthesis type 1. Am J Ophthalmol 2021;231:101–108.

27. Bostan C, Nayman T, Szigiato AA, Morfeq H, Harissi- Dagher M. Endophthalmitis in eyes with the Boston type I keratoprosthesis: Incidence, recurrence, risk factors, and outcomes. Cornea 2021;40:1258–1266.

28. Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MG, Dohlman CH. Keratoprosthesis: preoperative prognostic categories. Cornea 2001;20:19–23.

29. Zerbe BL, Belin MW, Ciolino JB; Boston Type 1 Keratoprosthesis Study Group. Boston Type 1 Keratoprosthesis Study Group. Results from the multicenter Boston type 1 keratoprosthesis study. Ophthalmology 2006;113:1779.e1–7.

30. Salvador-Culla B, Kolovou PE, Arzeno L, Martínez S, López MA. Boston keratoprosthesis type 1 in chemical burns. Cornea 2016;35:911–916.